SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Resectable NSCLCSeptember 24, 2026

Spread through air spaces carried an HR of 2.32 for DFS in stage 1 lung adenocarcinoma

Spread through air spaces was present in 54.2% of 378 stage 1 lung adenocarcinomas and carried an adjusted hazard ratio of 2.32 for disease-free survival, in a British Journal of Cancer study pairing whole exome and RNA sequencing with the histology. STAS entered the ninth edition of the TNM staging system as an adverse histologic feature, and the molecular features underlying it remain incompletely characterised.
Share

In brief

  • Among 378 patients with stage 1 lung adenocarcinoma and known status for spread through air spaces (STAS), 54.2% had STAS-positive tumours, at a similar rate in EGFR-mutant and EGFR-wildtype disease.
  • STAS remained independently associated with inferior disease-free survival after multivariable adjustment, with a hazard ratio of 2.32 (95% CI 1.16 to 4.63; p = 0.017).
  • STAS-positive tumours were significantly associated with stage 1B disease, lymphovascular invasion, higher histological grade, micropapillary or solid predominant subtype and a PD-L1 tumour proportion score of 1% or above.
  • On whole exome and RNA sequencing they were enriched for TP53 co-mutations, whole genome doubling, non-TRU transcriptomic subtypes and upregulated cell cycle pathways.
  • Those molecular findings pointed the same way in EGFR-mutant and in EGFR-wildtype tumours.

Study at a glance

  • Cohort: 378 patients with stage 1 lung adenocarcinoma and known STAS status
  • STAS incidence: 54.2%, similar in EGFR-mutant and EGFR-wildtype tumours
  • Methods: Whole exome and RNA sequencing of tumour samples with matched normal controls; disease-free survival by Kaplan-Meier method and Cox regression
  • Survival: Hazard ratio 2.32 (95% CI 1.16 to 4.63; p = 0.017) after multivariable adjustment
  • Histologic associations: Stage 1B disease, lymphovascular invasion, higher histological grade, micropapillary or solid predominant subtype, PD-L1 tumour proportion score 1% or above
  • Molecular findings: TP53 co-mutations, whole genome doubling, non-TRU transcriptomic subtypes, upregulated cell cycle pathways
  • Not reported: Overall survival and the duration of follow-up, neither of which appears in the published abstract

An adjusted hazard ratio of 2.32, on a feature present in over half the cohort

Just over half of these stage 1 tumours carried STAS, which makes it common rather than a marker of an unusual subset. Its incidence was much the same whether or not the tumour carried an EGFR mutation. It also travelled with stage 1B disease, lymphovascular invasion, higher grade, micropapillary or solid predominant subtype and a PD-L1 tumour proportion score of 1% or above, each reported as significant.

After multivariable adjustment STAS still stood on its own, with a confidence interval from 1.16 to 4.63. That interval spans a fourfold range, so the direction of the association is established while its size is not. The abstract does not name the covariates the model adjusted for, which a reader would need to judge how much of the histologic company STAS keeps is already in the estimate.

TP53 co-mutations, whole genome doubling and cell cycle upregulation

The sequencing found enrichment for TP53 co-mutations and whole genome doubling, with non-TRU transcriptomic subtypes and upregulation of cell cycle-related pathways, pointing the same way in EGFR-mutant and EGFR-wildtype tumours. In the authors’ reading those features amount to genomic instability and cell cycle dysregulation.

“STAS+ in stage 1 LUAD is associated with a distinct molecular phenotype characterised by genomic instability and cell cycle dysregulation, consistent with a more aggressive biological phenotype with implications for risk stratification and adjuvant therapy selection.”Saw et al., British Journal of Cancer (2026)

That conclusion is about which patients to pick out, and nothing here tests a treatment. No adjuvant regimen was given or compared, and no second cohort checked the molecular findings, so the work supports treating STAS as a marker worth stratifying on rather than a rule for who gets adjuvant therapy.

Sources

  1. British Journal of Cancer. Genomic and transcriptomic landscape of spread through air spaces in stage 1 lung adenocarcinoma (2026-09-19). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Stephanie Saw.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Patient Cases
Oct 04 2024
ILCS 2024
Advanced NSCLCResectable NSCLC

Patient Cases & Open Questions

} 32 min

Nuria Maria Novoa
Oct 04 2024
ILCS 2024
Resectable NSCLC

Surgical Dilemmas: Defining Resectability for Optimal Patient Outcomes in the IO Era

} 27 min

N. Novoa
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Nov132026
ILCS 2026

The International Lung Cancer Summit 2026

Learn more about the event

S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniL. ByersG. MountziosA. Dingemans
Oct252026
ESMO 2026 SYMPOSIUM
SCLC

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

Learn more about the event

M. ReckS. PetersG. MountziosN. Reguart
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
ILCS 2025
Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

A. Filippi
Sep 26 2025
ILCS 2025
Immunotherapies

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

P. Forde
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
ADCs

The ADC Revolution in Lung Cancer: New Targets, New Opportunities

} 27 min

N. Reguart
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Biomarkers

Cutting-Edge Diagnostic Techniques and Emerging Biomarkers

} 24 min

M. Ilié
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Articles
Sep 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw
Sep 17 2026
CONGRESS
Resectable NSCLCTargeted Therapies

Adjuvant osimertinib reduced the risk of death by 47% at eight years in ADAURA

Sep 15 2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Sep 14 2026
CONGRESS
Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

Sep 14 2026
CONGRESS
Resectable NSCLCTargeted Therapies

ADAURA at eight years: adjuvant osimertinib keeps a 15-point overall survival lead

Sep 12 2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC

WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response

Aug 31 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data

H. Horinouchi
Aug 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Fewer patients discontinued adjuvant alectinib than chemotherapy in ALINA, and quality-of-life gains held to two years

M. HochmairH. HorinouchiD. Planchard
Antonio Passaro
Aug 19 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC

T. CasconeP. FordeA. Passaro
Aug 13 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Pre-surgical ctDNA clearance reached 66% with neoadjuvant nivolumab against 38% with placebo in CheckMate 77T

T. Cascone
Aug 06 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Adjuvant crizotinib did not prolong DFS in resected ALK-positive NSCLC

J. Sands
Aug 02 2026
RESEARCH
Resectable NSCLCImmunotherapies

Five-year event-free survival was 49.9% with perioperative pembrolizumab against 26.5% with chemotherapy alone in KEYNOTE-671

D. Rodríguez-AbreuM. Reck
Portrait of Dr. Alexander Drilon
Sep 23 2026
CONGRESS
Advanced NSCLCTargeted Therapies

Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1

Sep 18 2026
INDUSTRY NEWS
Advanced NSCLCTargeted Therapies

Sevabertinib approved in the US for untreated HER2-mutant NSCLC

Sep 18 2026
CONGRESS
SCLCADCs

Ris-Rez improved OS against topotecan in relapsed SCLC in China

Sep 17 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Grade 3 adverse events on the FLAURA2 combination fell from 43% during induction to 14% on osimertinib alone

D. Planchard
Sep 16 2026
CONGRESS
Advanced NSCLCADCs

First-line trastuzumab deruxtecan extended median PFS to 14.3 months in HER2-mutant NSCLC

Sep 16 2026
CONGRESS
SCLCTargeted Therapies

Tam-Peli extended median OS to 13.3 months in relapsed SCLC, against 9.4 months with topotecan

Sep 15 2026
CONGRESS
Advanced NSCLCImmunotherapies

HARMONi-2: ivonescimab extends overall survival over pembrolizumab in China

Sep 14 2026
CONGRESS
Advanced NSCLCADCs

DESTINY-Lung04: first-line T-DXd adds six months of PFS, no interim survival gain